{"id":73795,"date":"2023-10-17T22:24:32","date_gmt":"2023-10-18T02:24:32","guid":{"rendered":"https:\/\/ifintechworld.com\/news\/embattled-embecta-continues-to-present-challenges-to-shareholder-value-nasdaqembc\/"},"modified":"2023-10-17T22:24:38","modified_gmt":"2023-10-18T02:24:38","slug":"embattled-embecta-continues-to-present-challenges-to-shareholder-value-nasdaqembc","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=73795","title":{"rendered":"Embattled Embecta Continues To Present Challenges To Shareholder Value (NASDAQ:EMBC)"},"content":{"rendered":"
\n

<\/picture>
<\/figcaption><\/figure>\n<\/p>\n

Investment Summary<\/h2>\n

The carve-out of Embecta Corp. (NASDAQ:EMBC<\/span>) from Becton, Dickinson (BDX) in April last year has failed to materialize a gain in shareholder wealth, with its equity stock selling at its lowest marks since the new listing. EMBC has diverged from key equity benchmarks and now has >9% short interest (which is high by the way), a clear indication of the negative sentiment priced into the stock. If equity prices are simply a set of discounted future expectations, then EMBC’s languished performance since the listing is telling of what the market foresees for this name.<\/span><\/p>\n

Following the latest investment updates (discussed here), it would appear there is little evidence to depart from the market’s appraisal. Its latest numbers did nothing to change the view, coming in weaker YoY at the top line, with demand clearly taking a hit in its U.S. operations, and no pricing benefits to speak of.<\/span><\/p>\n

Added to this, the following pressures lead me to believe EMBC is not an investment grade company at this point in time:<\/p>\n

    \n
  1. The balance sheet is saddled with debt, amounting to ~$1.6Bn in its fiscal Q3, with total liabilities exceeding gross assets by a factor of 1.64x.<\/li>\n
  2. Shareholders therefore are holding a negative equity value of ~$809mm.<\/li>\n
  3. Inventories on hand have increased at a rate 10x faster than quarterly top-line sales since its listing numbers in Q1 CY 2022 (44% vs. 4.4%, respectively).<\/li>\n
  4. Pre-tax income has diminished sequentially since early 2022. Using TTM values, it has compressed from $451.5mm to ~$290mm, 36% decline. Operating cash flows have followed suit.<\/li>\n
  5. The drivers of EMBC’s economic returns have also trended lower since listing and continue to do so.<\/li>\n<\/ol>\n

    This report will unpack each of these factors in greater detail, along with additional insights. Net-net, I continue to rate EMBC a hold.<\/p>\n

    Figure 1.<\/strong><\/p>\n

    \n

    \"f\"<\/span> <\/picture>
    \n

    Data: Updata<\/span><\/p>\n<\/figcaption><\/figure>\n<\/p>\n

    Critical facts pattern supporting reiterated buy rating<\/h2>\n

    1. Fundamentals + economic factors<\/h4>\n

    EMBC put up Q3 revenues of $286mm, down ~170bps YoY on gross profit of $203mm, equating to a 66% margin [As a reminder, EMBC reported its fiscal Q3 last period, corresponding to Q2 CY 2022]. <\/em>This is a compression of ~650bps YoY, correlating to operating margins of ~18%, down from 33% last year.<\/p>\n

    Management views the following guidance for this year:<\/p>\n

    (1). Sales growth of ~0.5\u20131%, calling for $1.14Bn at the upper end of range. It has done ~$840mm in sales so far this YTD, so it would be looking to ~$300mm in the final quarter of its fiscal ’23.<\/p>\n

    (2). No additional revenues concerning its contract manufacturing of non-diabetes products to BD.<\/p>\n

    (3). Gross margin of ~66%, up 150bps from prior guidance.<\/p>\n

    (4). Earnings of $2.75\u2013$2.80\/share, also up from prior estimates.<\/p>\n

    More critical to the debate is EMBC’s business returns since the carve-out last year. On that front, I’ve observed some concerning trends as it relates to the investment context.<\/p>\n

    For example, its post-tax earnings have compressed from $380mm in Q3 last year to $187mm last period (TTM values).<\/p>\n

    It has retained and recycled $108mm back into the business since March 2022. Total capital deployed into the business is now ~$756mm. On what investments have been made, the business returns EMBC is throwing off are actually quite attractive, totaling ~25% last period (TTM values).<\/p>\n

    A more thoughtful analysis is revealing of the true economics at play here. In particular, note the following:<\/p>\n